Compare NRG Energy Inc (NRG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Twist Bioscience Corp — how do they compare? NRG Energy Inc trades at $107.09 (market cap $22.35B), while Twist Bioscience Corp trades at $163.09 (market cap $10.08B). The key difference: NRG Energy Inc is far larger — about 2.2× Twist Bioscience Corp's market cap, and NRG Energy Inc pays a 1.79% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 62 Days and Twist Bioscience Corp for 27 Days on average.
| NRG | TWST | |
|---|---|---|
Market Cap | $22.35B | $10.08B |
Volume | 5,011,942 | 4,229,037 |
Sector | Utilities | Health |
52-Week High | $184.03 | $205.00 |
52-Week Low | $95.23 | $25.45 |
Typical Hold Time | 62 Days | 27 Days |
Enterprise Value | $46.30B | $10.01B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $107.24, down 1.26% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with 26.77% ROE and 2.56% net margin, though recent Q1 and Q2 2026 earnings missed expectations. Revenue growth remains positive, reaching $30.71B in 2025, while valuation metrics show a P/E of 27.69 and P/S of 0.65. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant.
Outlook remains positive with analyst consensus strongly bullish (70% buy ratings) and a $202.90 price target suggesting significant upside. Key risks include rising debt levels (56.42% debt-to-asset ratio) and execution challenges on major capital projects. The company's dual retail/generation model provides stability, but investors should monitor earnings delivery against high expectations.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
